A study of chest infections in HIV seropositive patients in Kuala Lumpur. NLM AIDSLINE Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


A study of chest infections in HIV seropositive patients in Kuala Lumpur.

Int J Clin Pract. 1998 Jan-Feb;52(1):23-6. Unique Identifier : AIDSLINE MED/98197628
Wood E; Cheong I; Lee C; Department of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur,; Malaysia.

Abstract: A retrospective study of 144 adults with HIV infection was conducted to investigate the prevalence of upper and lower respiratory tract infections (URTIs and LRTIs). The patients were divided into two groups: those with acquired HIV through intravenous drug abuse (IVDA), and those who had acquired HIV through 'other' risk behaviours. LRTIs were more prevalent than URTIs overall, and LRTIs were significantly more common (p < 0.001) in IVDAs than in the other-risk group. Tuberculosis (40%) and bacterial pneumonias (33%) comprised the majority of LRTIs among IVDAs, while Pneumocystis carinii pneumonia (40%) was the commonest LRTI in the other-risk group. Analysis of CD4 T-lymphocyte counts indicated that HIV-seropositive IVDAs are at greater risk of developing chest infections at higher CD4 counts than other-risk patients. The IVDAs were also found to have a much higher rate of co-infection with hepatitis C and B, which may be a factor accelerating the progression from HIV infection to AIDS. The mean time averaged for the two groups from known seroconversion to development of respiratory tract infection is only 1.37 years, which suggests HIV-infected patients are presenting late for treatment in Malaysia.
Keywords: *AIDS-Related Opportunistic Infections/COMPLICATIONS *HIV Seropositivity/COMPLICATIONS *Respiratory Tract Infections/COMPLICATIONS *Respiratory Tract Infections/EPIDEMIOLOGY *Substance Abuse, Intravenous/COMPLICATIONS *Substance Abuse, Intravenous/EPIDEMIOLOGY

KWDaids-relatedopportunisticinfections/complicationsKWDhivseropositivity/complicationsKWDrespiratorytractinfections/complicationsKWDrespiratorytractinfections/epidemiologyKWDsubstanceabuse,intravenous/complicationsKWDsubstanceabuse,intravenous/epidemiology
980730
M9871332

Copyright © 1998 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .